Division of Gastroenterology, University of Puerto Rico, San Juan, Puerto Rico.
Hospital Bella Vista, Mayagüez, Puerto Rico.
Surg Endosc. 2022 Jul;36(7):5160-5166. doi: 10.1007/s00464-021-08892-2. Epub 2021 Nov 29.
Obesity is an expanding public health problem, resulting in more than half a billion adults worldwide. Intragastric balloon (IGB) placement is a weight loss alternative for obese patients with an inadequate weight loss response to diet and exercise. The aim of this study is to examine the efficacy and safety of the single-chamber fluid-filled IGB for weight loss and compare its results across different age groups.
We performed a database review of 239 consecutive patients from two outpatient GI clinics who underwent placement of an IGB. Our final analysis composed of 239 IGB placements in 232 patients (mean age, 44.5 ± 10.3 years; 67% female; baseline BMI 42.0 ± 9.0). Efficacy outcomes included the percentage of the total (%TWL) and excess weight loss (%EWL). Safety outcomes were measured as the number of patients who required early IGB removal (before 6 months).
%TWL at 3 months was 10.1% and 14.4% at 6 months. Overall, 92%, 74%, and 47% of patients lost 5%, 10%, and 15% of total weight at 6 months, respectively. %EWL was 22.1% and 30.7% at 3 and 6 months post-IGB placement, respectively. The balloon was safely removed at six months after placement in most patients, whereas in 13.0% of cases early removal was performed at an average of 12.0 weeks after placement (range, 2 days-23 weeks).
The use of a single-chamber fluid-filled IGB is successful in inducing a significant amount of weight loss in almost three-fourths of patients six months after its placement. This beneficial effect is seen across different BMI ranges and age groups at a similar level. IGBs should be considered an effective and safe alternative for obese patients who fail lifestyle interventions and conservative measures, fulfilling the unmet needs of many who are unwilling or unable to undergo bariatric surgery.
肥胖是一个不断扩大的公共卫生问题，导致全球有超过 5 亿成年人受到影响。胃内球囊（IGB）放置是一种针对肥胖患者的减肥替代方法，这些患者对饮食和运动的减肥反应不足。本研究旨在检查单室充液型 IGB 对减肥的疗效和安全性，并比较其在不同年龄组的结果。
我们对两家胃肠门诊的 239 例连续患者进行了数据库回顾，这些患者均接受了 IGB 放置。我们的最终分析包括 232 例患者的 239 个 IGB 放置（平均年龄 44.5±10.3 岁；女性占 67%；基线 BMI 为 42.0±9.0）。疗效结果包括总重量减轻百分比（%TWL）和多余体重减轻百分比（%EWL）。安全性结果测量为需要早期（放置后 6 个月内）移除 IGB 的患者数量。
放置后 3 个月时的 %TWL 为 10.1%，6 个月时为 14.4%。总体而言，6 个月时分别有 92%、74%和 47%的患者减轻了 5%、10%和 15%的总体重。放置后 3 个月和 6 个月时的 %EWL 分别为 22.1%和 30.7%。大多数患者在放置后 6 个月时安全地移除了球囊，而在 13.0%的情况下，在放置后平均 12.0 周（2 天至 23 周）时进行了早期移除。
使用单室充液型 IGB 可在放置后 6 个月内成功诱导近四分之三的患者显著减重。这种有益的效果在不同 BMI 范围和年龄组中以相似的水平出现。IGB 应被视为对生活方式干预和保守治疗失败的肥胖患者的有效和安全替代方法，满足了许多不愿意或无法接受减重手术的患者的未满足需求。
